RBS070412 is a kinase inhibitor drug that was developed and patented by Oncque, a biotech company based in France. It is a potent, ATP-competitive inhibitor of both wild-type and mutant forms of the protein kinase CK2, which is involved in several cancer cell activities. RBS070412 shows promising activity against a range of cancer cell lines, including those which have developed drug resistance, indicating its potential for future therapeutic use. In addition, it has also been demonstrated to induce apoptosis and inhibit cancer-cell proliferation in vitro. The drug has yet to be tested in humans.